Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.88 |
| ▸ | MEN1 | O00255 | 2/20 | 0.88 |
| ▸ | TSHR | P16473 | 2/20 | 0.78 |
| ▸ | TET3 | O43151 | 1/20 | 0.53 |
| ▸ | FBXL19 | Q6PCT2 | 1/20 | 0.53 |
| ▸ | CXXC5 | Q7LFL8 | 1/20 | 0.53 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.53 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.53 |
| ▸ | CXXC4 | Q9H2H0 | 1/20 | 0.53 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | PLA2G4B | P0C869 | 2/20 | 0.50 |
| ▸ | RARB | P10826 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4342214 | 0.87 | KMT2A (0.68) | KMT2AMEN1TSHRTET3FBXL19 | |
| SCHEMBL7507062 | 0.86 | KMT2A (0.71) | KMT2AMEN1TSHRTET3FBXL19 | |
| SCHEMBL10886888 | 0.84 | MEN1 (0.68) | KMT2AMEN1TSHRTP53PLA2G4B | |
| SCHEMBL10319694 | 0.84 | KMT2A (0.64) | KMT2AMEN1TSHRTET3FBXL19 | |
| SCHEMBL15578258 | 0.84 | KMT2A (0.64) | KMT2AMEN1TSHRTET3FBXL19 | |
| SCHEMBL7511985 | 0.83 | KMT2A (0.67) | KMT2AMEN1TSHRTET3FBXL19 | |
| SCHEMBL9855788 | 0.83 | KMT2A (0.62) | KMT2AMEN1TSHRTET3FBXL19 | |
| SCHEMBL15578198 | 0.82 | KMT2A (0.62) | KMT2AMEN1TSHRTET3FBXL19 | |
| SCHEMBL8078676 | 0.81 | KMT2A (0.64) | KMT2AMEN1TSHRTET3FBXL19 | |
| SCHEMBL11232365 | 0.81 | KMT2A (0.73) | KMT2AMEN1TSHRTET3FBXL19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968550-B2 | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2011-06-28 | — | — | US | disclosed |
| US-20070207991-A1 | Substituted N-aryl Heterocycles, Process For Their Preparation and Their Use As Medicaments | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-09-06 | — | — | US | disclosed |
| US-7223788-B2 | therapy for eating disorders, anorexigenic agents, antidiabetic agents, reducing weight in mammals, circadian rhythm disease, psychological disorders | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-05-29 | — | — | US | disclosed |
| EP-1597228-A2 | SUBSTITUTED N-ARYLHETEROCYCLES, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENTS | Sanofi-Aventis Deutschland GmbH (DE) | 2005-11-23 | — | — | EP | disclosed |
| US-20040220191-A1 | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-11-04 | — | — | US | disclosed |
| WO-2004072025-A2 | SUBSTITUTED N-ARYLHETEROCYCLES, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENTS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220191-A1 | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments | CYP11B2, CYP11B1, CYP1A1 | KMT2A 4317/4885MEN1 982/4885TSHR 3707/4885 |
| US-20070207991-A1 | Substituted N-aryl Heterocycles, Process For Their Preparation and Their Use As Medicaments | CYP11B2, CYP11B1, NQO1 | KMT2A 4320/4885MEN1 1308/4885TSHR 3597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.